Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Schering makes flurry of moves
September 25, 2006
| A version of this story appeared in
Volume 84, Issue 39
On the verge of being acquired by Bayer, Schering is adjusting its collaborations in the pharmaceutical field. It has formed an alliance with AstraZeneca to codevelop a Schering selective estrogen receptor downregulator as a breast cancer treatment. It has granted Bausch & Lomb an exclusive license to develop a selective glucocorticoid receptor agonist for the treatment of eye disorders. And it has ended a research collaboration with Organon in the area of male contraception, after determining that the required injections would inhibit widespread use.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter